Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

Stopped early · Phase 4

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to determine whether standard medications approved for Alzheimer's disease treatment differ in their action on brain functioning and whether any observed brain activity differences as result of treatment are associated with particular patterns of dementia improvement or reduced decline.

Key facts

Study ID

NCT00369603

Run by

Duke University

People needed

4

Starts

2006-10-01

Expected to finish

2007-11-01

Last updated by the study team

2013-04-11

Who can join

Age: 40 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must meet diagnosis of mild Alzheimer's disease
• Must have a family member or caregiver who is willing to attend all study visits and provide information on your participation in the study
• If female, must be post-menopausal
• Must be able to swallow tablets

You may not qualify if…

• Metal implants or medical devises unsafe for MRI use
• Pre-menopausal female
• HIstory of recent head injury
• Significant major, life-threatening illness or injury (e.g., stroke, AIDS, etc.)
• Vascular dementia or any dementia other than Alzheimer's Disease
• History of significant alcoholism or drug abuse
• History of seizure disorder, developmental delay or major psychiatric illness

Where it is running

• Joseph & Kathleen Bryan Alzheimer's Disease Research Unit — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.